EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni

Ying-Chou Chen, Yueh-Lun Lee, Ching-An Lee, Tzu-Yuan Lin, Edwin En-Te Hwu, Po-Ching Cheng iD

PLOS Neglected Tropical Diseases · 12.09.2024 · 18 (9) · e0012502

DOI: 10.1371/journal.pntd.0012502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 12.09.2024. Verfasst von Ying-Chou Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Liver Cirrhosis, RNA, Small Interfering, Schistosoma mansoni, Schistosomiasis mansoni. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taipei, Taiwan to Po-Ching Cheng, LEO Foundation, Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schistosoma mansoni infection leads to chronic schistosomiasis and severe hepatic fibrosis. We designed a liver-targeted lipid nanoparticle (LNP) carrying siRNA against type I TGF-β receptor (TGFβRI) mRNA to treat schistosomiasis-induced liver fibrosis in BALB/c mice. Knockdown of TGFβRI by LNP-siTGFβRI reduced LX-2 cell activation in vitro and alleviated liver fibrosis in S . mansoni -infected mice. αSMA and Col1a1 fibrotic markers in the liver tissues of infected mice were significantly suppressed in the treatment groups. In the serum of the LNP-siTGFβRI-treated groups, cytokines IFNγ, IL-1α, IL-6, IL-12, RANTES (CCL5), and TNFα increased, while GM-CSF, IL-2, IL-4, IL-10, IL-13, and KC (CXCL1) decreased compared to the control. Cell proportions were significantly altered in S . mansoni -infected mice, with increased CD56d NK cells and decreased CD19 + B cells and CD4 + T cells compared to naïve mice. Following LNP-siTGFβRI treatment, CD56d NK cells were downregulated, while B and memory Th cell populations were upregulated. The density of fibrotic regions significantly decreased with LNP-siTGFβRI treatment in a dose-dependent manner, and no systemic toxicity was observed in the major organs. This targeted siRNA delivery strategy effectively reduced granulomatous lesions in schistosomiasis-induced liver fibrosis without detectable side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisRNA, Small InterferingSchistosoma mansoniSchistosomiasis mansoniAnimalsFemaleHumansMiceCytokinesLipidsLiverMice, Inbred BALB CNanoparticles

Substanzen

CytokinesLipidsRNA, Small Interfering

Autor:innen und Institutionen

  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Molecular Parasitology and Tropical Diseases, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Drug Metabolism & Pharmacokinetics Department, Institute for Drug Evaluation Platform, Development Center for Biotechnology, Taipei, Taiwan.
  • Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, Taiwan.
  • The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics, Department of Health Technology, Technical University of Denmark.
  • Center for International Tropical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Po-Ching Cheng

Förderung

  • Ministry of Science and Technology, Taipei, Taiwan to Po-Ching Cheng
  • LEO Foundation
  • Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics
  • Ministry of Science and Technology, Taiwan
  • LEO Fondet

Zitieren

APA

Chen, Y. C., Lee, Y. L., Lee, C. A., Lin, T. Y., Hwu, E. E., & Cheng, P. C. (2024). Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni. PLOS Neglected Tropical Diseases, 18(9), e0012502. https://doi.org/10.1371/journal.pntd.0012502

Vancouver

Chen YC, Lee YL, Lee CA, Lin TY, Hwu EE, Cheng PC. Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni. PLOS Neglected Tropical Diseases. 2024;18(9):e0012502. doi:10.1371/journal.pntd.0012502

BibTeX
@article{Chen2024,
  author = {Chen, Ying-Chou and Lee, Yueh-Lun and Lee, Ching-An and Lin, Tzu-Yuan and Hwu, Edwin En-Te and Cheng, Po-Ching},
  title = {Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  volume = {18},
  number = {9},
  pages = {e0012502},
  doi = {10.1371/journal.pntd.0012502}
}
Kostenlos starten →